GlassScriptPhysician profile
Amanda Tessitore
NPI 1528707494
$1,472.94
in general payments reported to CMS, 2019-2025
23 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $451 · 2023: $180 · 2024: $484 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,021.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $237.03 | 2024-2025 | Lux-Dx Insertable Cardiac Monitor, General - Brady, Bodyguardian |
| Pfizer INC. | $167.51 | 2022-2024 | |
| Medtronic, INC. | $157.86 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $152.85 | 2022-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $108.64 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.44 | 2022-2025 | Jardiance |
| Amgen INC. | $86.20 | 2023-2025 | Repatha, Repatha |
| Abiomed | $72.84 | 2024 | Impella |
| Chiesi USA, INC. | $61.71 | 2022-2024 | Kengreal, Cleviprex |
| Kiniksa Pharmaceuticals International, Plc | $45.12 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $43.60 | 2024 | |
| Janssen Pharmaceuticals, INC | $40.53 | 2022-2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $24.63 | 2023 | Evkeeza |
| Actelion Pharmaceuticals US, INC. | $22.08 | 2024 | Uptravi |
| Bridgebio Pharma, INC. | $19.66 | 2025 | Attruby |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.59 | 2025 | Verquvo |
| Heartflow, INC. | $18.75 | 2024 | |
| Inspire Medical Systems, INC. | $18.74 | 2025 | Inspire |
| Daiichi Sankyo INC. | $18.60 | 2024 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $18.34 | 2024 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $15.86 | 2025 | |
| Alexion Pharmaceuticals, INC. | $14.90 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.46 | 2023 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Tessitore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.